Market Overview

Maxim Raises Target On bluebird bio From $85 To $100, Maintains Buy Rating

Share:

With the only drug candidate that was close to approval for sickle cell now off the table, Maxim’s Jason McCarthy believes that bluebird bio Inc (NASDAQ: BLUE) could see a larger opportunity for its gene therapy, LentiGlobin.

McCarthy maintained a Buy rating on the company, while raising the price target from $85 to $100.

Larger Opportunity

The analyst mentioned it had previously been assumed, due to the perceived risk of the therapy, that LentiGlobin could be an option for only about 3 percent of the patients.

“We spent time with patients, several of whom had undergone allogeneic stem cell transplant, and transplant doctors, and learned that the technology and safety for an allo BMT have improved so much that it's a viable option for more and more patients,” McCarthy went on to say.

The analyst explained that these doctors and patients appeared to be more open to gene therapy than had earlier been expected, which meant that there could be a potentially larger market opportunity for LentiGlobin in sickle cell.

Estimates Revised

McCarthy now assumes the therapy would be accessible to up to 10 percent of sickle cell patients, while the price estimate has been lowered from $750,000 to $500,000, given the larger opportunity.

“Sickle cell drug development continues to struggle with only one drug approved. While many drugs are in development that may ultimately get to approval (or fail), we believe more and more patients may turn to gene therapy as a remedy,” the analyst added.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for BLUE

DateFirmActionFromTo
Nov 2020BerenbergInitiates Coverage OnBuy
Nov 2020Morgan StanleyMaintainsEqual-Weight
Nov 2020Piper SandlerMaintainsNeutral

View More Analyst Ratings for BLUE
View the Latest Analyst Ratings

 

Related Articles (BLUE)

View Comments and Join the Discussion!

Posted-In: Jason McCarthy LentiGlobin MaximAnalyst Color Long Ideas Price Target Analyst Ratings Trading Ideas

Latest Ratings

StockFirmActionPT
PMTB of A SecuritiesMaintains18.5
IVRB of A SecuritiesMaintains3.0
EFCB of A SecuritiesMaintains15.5
NYMTB of A SecuritiesMaintains3.5
NLYB of A SecuritiesMaintains8.5
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com